Two-year treatment outcome of photodynamic therapy combined with anti-vascular endothelial growth factor therapy for pachychoroid neovasculopathy

IF 2.6 3区医学 Q2 ONCOLOGY

Photodiagnosis and Photodynamic Therapy Pub Date : 2025-07-31 DOI:10.1016/j.pdpdt.2025.104746

Sayaka Uemura, Akiko Miki, Maya Kishimoto-Kishi, Aya Chubachi-Kamimura, Makoto Nakamura

{"title":"Two-year treatment outcome of photodynamic therapy combined with anti-vascular endothelial growth factor therapy for pachychoroid neovasculopathy","authors":"Sayaka Uemura, Akiko Miki, Maya Kishimoto-Kishi, Aya Chubachi-Kamimura, Makoto Nakamura","doi":"10.1016/j.pdpdt.2025.104746","DOIUrl":null,"url":null,"abstract":"<div><h3>Objective</h3><div>To investigate the two-year treatment outcomes of photodynamic therapy (PDT) combined with intravitreal anti-vascular endothelial growth factor (anti-VEGF) therapy in patients with pachychoroid neurovasculopathy (PNV).</div></div><div><h3>Methods</h3><div>A retrospective study was conducted on 22 eyes of 22 treatment-naïve patients diagnosed with PNV who underwent combination therapy with PDT and intravitreal anti-VEGF agents (ranibizumab or aflibercept). Patients were followed for at least two years after treatment and evaluated for visual acuity (VA), central retinal thickness (CRT), subfoveal choroidal thickness (SCT), presence of recurrent exudative changes, time to recurrence, and additional treatments.</div></div><div><h3>Results</h3><div>The study involved 12 male and 10 female patients with a mean age of 64.1 ± 11.5 years. Baseline VA (0.16±0.26) improved significantly at 6 months (0.05 ± 0.23; <em>P</em> < 0.01), which was maintained until 24 months (0.04 ± 0.22; <em>P</em> < 0.01). Baseline CRT and SCT (303.1 ± 105.0 μm and 362.5 ± 83.8 μm, respectively) showed significant reductions at one month after treatment (184.5 ± 56.9 μm and 307.7 ± 94.6 μm; both <em>P</em> < 0.001), which were maintained until 24 months (170.8 ± 42.9 μm and 286.2 ± 99.1 μm; both <em>P</em> < 0.001). Recurrence was observed in five eyes (22.7 %) at a mean recurrence interval of 8.5 ± 3.9 months. The mean number of additional PDT and anti- VEGF treatments was 0.2 ± 0.4 and 1.9 ± 4.5, respectively.</div></div><div><h3>Conclusions</h3><div>Combination therapy with PDT and intravitreal anti-VEGF may be effective in improving visual acuity and anatomy in patients with PNV.</div></div>","PeriodicalId":20141,"journal":{"name":"Photodiagnosis and Photodynamic Therapy","volume":"55 ","pages":"Article 104746"},"PeriodicalIF":2.6000,"publicationDate":"2025-07-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Photodiagnosis and Photodynamic Therapy","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1572100025002789","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Objective

To investigate the two-year treatment outcomes of photodynamic therapy (PDT) combined with intravitreal anti-vascular endothelial growth factor (anti-VEGF) therapy in patients with pachychoroid neurovasculopathy (PNV).

Methods

A retrospective study was conducted on 22 eyes of 22 treatment-naïve patients diagnosed with PNV who underwent combination therapy with PDT and intravitreal anti-VEGF agents (ranibizumab or aflibercept). Patients were followed for at least two years after treatment and evaluated for visual acuity (VA), central retinal thickness (CRT), subfoveal choroidal thickness (SCT), presence of recurrent exudative changes, time to recurrence, and additional treatments.

Results

The study involved 12 male and 10 female patients with a mean age of 64.1 ± 11.5 years. Baseline VA (0.16±0.26) improved significantly at 6 months (0.05 ± 0.23; P < 0.01), which was maintained until 24 months (0.04 ± 0.22; P < 0.01). Baseline CRT and SCT (303.1 ± 105.0 μm and 362.5 ± 83.8 μm, respectively) showed significant reductions at one month after treatment (184.5 ± 56.9 μm and 307.7 ± 94.6 μm; both P < 0.001), which were maintained until 24 months (170.8 ± 42.9 μm and 286.2 ± 99.1 μm; both P < 0.001). Recurrence was observed in five eyes (22.7 %) at a mean recurrence interval of 8.5 ± 3.9 months. The mean number of additional PDT and anti- VEGF treatments was 0.2 ± 0.4 and 1.9 ± 4.5, respectively.

Conclusions

Combination therapy with PDT and intravitreal anti-VEGF may be effective in improving visual acuity and anatomy in patients with PNV.

查看原文本刊更多论文

光动力疗法联合抗血管内皮生长因子治疗厚脉络膜血管病两年疗效观察。

目的：探讨光动力疗法（PDT）联合玻璃体内抗血管内皮生长因子（anti-VEGF）治疗厚脉络膜神经血管病变（PNV） 2年的疗效。方法：回顾性研究22例treatment-naïve确诊PNV患者的22只眼，采用PDT联合玻璃体内抗vegf药物（雷尼单抗或阿非利西普）治疗。患者在治疗后随访至少两年，并评估视力（VA）、视网膜中央厚度（CRT）、中央凹下脉络膜厚度（SCT）、复发性渗出改变的存在、复发时间和其他治疗。结果：男性12例，女性10例，平均年龄64.1±11.5岁。6个月时基线VA（0.16±0.26）显著改善（0.05±0.23）；P < 0.01)，维持至24个月(0.04±0.22；P < 0.01)。基线CRT和SCT（分别为303.1±105.0 μm和362.5±83.8 μm）在治疗后1个月显着降低（184.5±56.9 μm和307.7±94.6 μm）；P < 0.001)，维持至24个月（170.8±42.9 μm和286.2±99.1 μm）；P均< 0.001)。复发5眼（22.7%），平均复发间隔8.5±3.9个月。额外PDT治疗和抗VEGF治疗的平均次数分别为0.2±0.4和1.9±4.5次。结论：PDT联合玻璃体内抗vegf治疗可有效改善PNV患者的视力和解剖结构。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Photodiagnosis and Photodynamic Therapy ONCOLOGY-

CiteScore

5.80

自引率

24.20%

发文量

509

审稿时长

50 days

期刊介绍： Photodiagnosis and Photodynamic Therapy is an international journal for the dissemination of scientific knowledge and clinical developments of Photodiagnosis and Photodynamic Therapy in all medical specialties. The journal publishes original articles, review articles, case presentations, "how-to-do-it" articles, Letters to the Editor, short communications and relevant images with short descriptions. All submitted material is subject to a strict peer-review process.